Harmony Biosciences Q4 2022 net revenue $128.3M (+41% YoY); full-year net income $181.5M

Harmony Biosciences Holdings, Inc.

2022-FY EPS reported $2.97 revenue$437,855,000

Q4 net product revenue $128.3M, up 41% YoY; average patients on WAKIX ~4,900.
GAAP net income Q4 $48.5M ($0.79 diluted EPS); non-GAAP adjusted $61.9M ($1.01).
Full year 2022 net revenue $437.9M (+43% YoY); net income $181.5M.
Phase 3 idiopathic hypersomnia INTUNE study continues with strong momentum.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 21, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-001572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.